105 CMR 720.00 — List of interchangeable drug products

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

105 CMR 720.000: LIST O F IN TERCHAN GEABLE DRUG PRO DUCTS Section

105 CMR 720.00 List of interchangeable drug products

720.001 Purpose

720.001: Purpose

720.002 Citation

720.002: Citation

720.010 Scope and Application

720.010: Scope and Application

720.020 Definitions

720.020: Definitions Standards 720:040: Commission Review of Relevant Drug Products

720.050 List of Interchangeable Drug Products

720.050: List of Interchangeable Drug Products

720.060 Drug Products Excluded

720.060: Drug Products Excluded

720.070 Amendments to the Massachusetts List of Interchangeable Drugs

720.070: Amendments to the Massachusetts List of Interchangeable Drugs Procedures for Amending List of Interchangeable Drug Products

720.080 Procedures for Amending the Massachusetts List of Interchangeable Drugs

720.080: Procedures for Amending the Massachusetts List of Interchangeable Drugs

720.081 Petition to Amend List of Interchangeable Drug Products

720.081: Petition to Amend List of Interchangeable Drug Products

720.082 Commission Review of Petition

720.082: Commission Review of Petition

720.083 Notice of Public Comment Period

720.083: Notice of Public Comment Period

720.084 Commission Recommendation of Amendments to Department

720.084: Commission Recommendation of Amendments to Department

720.090 Department Adoption of Amendments

720.090: Department Adoption of Amendments

720.100 Severability

720.100: Severability

720.200 Appendix A: List of Interchangeable Drugs

720.200: Appendix A: List of Interchangeable Drugs

720.001 Purpose

720.001: Purpose The purpose of 105 CMR 720.000 is to establish a drug formulary, or list of interchangeable drug products, for use by physicians, other practitioners, and pharmacists licensed to practice within the commonwealth, so that consumers of prescription drug products may realize cost savings by buying less expensive, safe drug products.

720.002 Citation

720.002: Citation 105 CMR 720.000 shall be known as the 105 CMR 720.000: Massachusetts List of Interchangeable Drug Products.

720.010 Scope and Application

720.010: Scope and Application 105 CMR 720.000 establishes the list of interchangeable drug products from which a pharmacist must interchange a reasonably available less expensive drug product than that written, when a prescription written by a practitioner indicates "interchange". 105 CMR 720.000 also establishes criteria and procedures for inclusion of drug products on this list.

720.020 Definitions

720.020: Definitions The terms used herein shall have the meanings set forth below. Terms defined in M.G.L. c. 112, § 12D and c. 94C, § 1, and not defined herein shall have the meanings set forth therein when used in 105 CMR 720.000, unless the context clearly requires a different interpretation. Bioequivalent Drug Products means drug products whose rate and extent of absorption do not show a significant difference when administered at the same molar dose of therapeutic moiety under similar conditions. Some drug products may be equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered therapeutically equivalent because such differences in the rate ofabsorption are not essential to the attainment of effective body drugconcentrations or are considered medically insignificant for the particular drug product studies.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.020 continued

720.020: continued Drug products for which bioequivalence is considered essential are those whose bioinequivalence would have therapeutic significance, i.e. use of different brands of the same drug product or different batches of the same drug product would result in therapeutic failure or a hazard to the patient. This is most critical in a drug product that has a narrow therapeutic-toxicity range which requires careful patient titration and monitoring for safe and effective use. Commissioner means the commissioner of public health appointed under M.G.L. c. 17, § 2. Department means the Department of Public Health established under M.G.L. c. 17 as an agency within the Executive Department of the Commonwealth of Massachusetts. Drug Product means a product which contains an active drug ingredient and is in a dosage form, e.g. tablet, capsule, or solution, generally, but not necessarily in combination with other substances included in the manufacturing process. An active drug ingredient is that portion of a drug product intended to produce a therapeutic effect. FDA means the Food and Drug Administration of the United States Department of Health and Human Services. Generic name means a non-proprietary (common) name used to identify a drug product as listed by the United States Adopted Names Council and the United States Pharmacopeia in the USAN/USP Dictionary of Drug Names. Interchangeable Drug Product means a product containing a drug in the same amounts of the same active ingredients in the same dosage form as other drug products with the same generic or chemical na me . Pharmaceutically equivalent drug products means drug p ro d ucts which contain the same active ingredients, and are identical in strength or concentration, dosage form, and route of administration. Public Health Council means the Department's governing body established under M.G.L. c. 17, § 3. See also M.G.L. c. 111, § 3. Therapeutically equivalent drug products means drug products which are pharmaceutically equivalent; meet applicable standards for strength, quality, purity and identity; are bioequivalent in that: (a) they do not present a known or potential bioequivalence problem, and they do meet an acceptable in vitro standard; or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standards matching both rate and extent of absorption; are adequately labeled; and are manufactured in compliance with current Good Manufacturing Practice regulations.

720.040 Commission Review of Relevant Drug Products

720.040: Commission Review of Relevant Drug Products In preparing the List of Interchangeab le Drug Products and amendments thereto, the Drug Formulary Commissio n shall determine whether drug products meet the standards set forth in 105 CMR 720.050. In making this determination, the Commission shall assess and evaluate pertinent data, including, but not limited to, the United States Pharmacopeia and its supplements, additional pertinent listings of the FDA, other state formularies, formularies of various hospitals of the commonwealth, and data submitted by manufacturers and other interested persons, including chemical and laboratory listing data and clinical evidence concerning bioequivalence and therapeutic equivalence where available. In reviewing this material, the Commission shall utilize the pharmaceutical and medical expertise of its members.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.050 List of Interchangeable Drug Products

720.050: List of Interchangeable Drug Products The Massachusetts List of Interchangeable Drug Products (MLID) shall consist of: (1) drug products which are considered by FDA to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name according to the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the United States Department of Health and Human Services: (2) drug products specified on a list established by the Department and set forth in 105 CMR 720.200, for which the Commission has determined that the bioequivalence is not essential, or if the Commission has determined that the bioequivalence may be essential, bioequivalence has been established. The list may include the following categories of drug products: (a) drug products which hold New Drug Applications (NDAs) or Abb reviated New Drug Applications (ANDAs) approved by the FDA, which FDA does not consider to be therapeutically equivalent to other pharmaceutically equivalent products listed with the same generic or chemical name; and (b) drug products exempt from the Food, Drug and Cosmetic Act of 1962, and included in the Drug Efficacy Study Implementation (DESI) done by the National Academy of Sciences/National Research Council; and (c) frequently prescribed drug products which were manufactured prior to 1938 and meet the FDA Good Manufacturing Practices Requirements; and (d) frequently prescribed over-the-counter drug products which contain the same amounts of active ingredients, in the same dosage forms, as other drug products with the same general or c he mic a l na me .

720.060 Drug Products Excluded

720.060: Drug Products Excluded The following categories of drug p roducts are excluded from the list of interchangeable drug products: (a) drug products for which the Commonwealth has determined that bioequivalence may be essential, but for which bioequivalence has not been established; and (b) drug products which are the subject matter of patent rights issued by the U.S. Patent Office, for which provision by other than the patent-holder would violate the patent; and (c) drug products available from only one manufacturer at one price.

720.070 Amendments to the Massachusetts List of Interchangeable Drugs

720.070: Amendments to the Massachusetts List of Interchangeable Drugs (1) Drug products which meet the criteria specified in 105 CMR 720.050(1) shall be deemed interchangeable and added to the Massachusetts List of Drugs upon publication by the United States Department of Health and Human Services of the most recent edition of "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements. (2) Drug products which meet criteria specified in 105 CMR 720.050(2) shall be deemed interchangeable and added to the Massachusetts List of Interchangeable Drugs in accordance with procedures set forth in 105 CMR 720.080.

720.080 Procedures for Amending the Massachusetts List of Interchangeable Drugs

720.080: Procedures for Amending the Massachusetts List of Interchangeable Drugs The Department, working with the Commission, shall review at least one a year and revise as necessary the list of interchangeable drug products adopted pursuant to 105 CMR 720.050(2), and shall have the authority to review and revise the list of interchangeable drug products adopted pursuant to 105 CMR 720.050(1) as necessary. The revisions to 105 CMR 720.050(1) shall be specified on an exception list established by the Department and set forth in 105 CMR 720.200. The revisions will add and delete drug products, based on current information concerning therapeutic efficacy and interchangeability of drug products.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.081 Petition to Amend List of Interchangeable Drug Products

720.081: Petition to Amend List of Interchangeable Drug Products Any person who desires a drug product or products to be added to or deleted from the List of Interchangeable Drug Products, shall file a written petition with the Department to amend the List, pursuant to M.G.L. c. 30A, § 4. Each petition shall be in such form as the Department may require and shall be submitted to the Drug Formulary Commission.

720.082 Commission Review of Petition

720.082: Commission Review of Petition Upon receipt of a petition, the Department shall submit the petition and the supporting information to the Commissionfor review. The Commission shall make a preliminary determination whether the List of Interchangeable Drug Products should be amended as proposed.

720.083 Notice of Public Comment Period

720.083: Notice of Public Comment Period Upon completion of the review of all relevant information, including petitions, by the Commission, the Department shall propose amendments to the List of Interchangeable Drug Products by issuing a Notice of Public Comment Period pursuant to M.G.L. c. 30A, §§ 2 and 3. The Department shall mail a Notice of Public Comment Period to each person who filed a petition during the period ending 30 days before the Notice of Public Comment Period is issued. In addition, the Department shall mail a Notice of the Public Comment Period to each person who has filed a written request therefore with the Department during December of the previous year pursuant to M.G.L. c. 30A, § 2.

720.084 Commission Recommendation of Amendments to Department

720.084: Commission Recommendation of Amendments to Department Following the comment p e riod Department staff shall review all evidence and commentary concerning the proposed amendments, and shall report its recommendation to the Commission. The Commission shall consider the staff recommendations, make such revisions as it deems appropriate, and shall recommend Amendments to the List of Interchangeable Drug Products for adoption by the Commissioner and the Public Health Council.

720.090 Department Adoption of Amendments

720.090: Department Adoption of Amendments The Commissioner and the Public Health Council shall consider the recommendations of the Drug Formulary Commission, and shall adopt Amendments to the List of Interchangeable Drug Products.

720.100 Severability

720.100: Severability The provisions of 105 CMR 720.000 are severable. If any provision shall be declared invalid by any court, such provision shall be null and void and such determination shall not affect or impair any of the remaining provisions. REGULATO RY AUTHO RITY 105 CMR 720.000: M.G.L. c. 17, § 13; c. 112, § 12D.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 Appendix A

720.200: Appendix A M ASSACHUSETTS

LIST OF

INTERCHANGEABLE DRUGS

Department of Public Health regulation 105 CMR 720.050 describes the Massachusetts List of Interchangeable Drugs. 105 CMR 720.050(a) calls for the automatic adoption of all "A" rated drug products listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the U.S. Food and Drug Administration (FDA), Department of Health and Human Services. This publication is commonly referred to as the "Orange Book". It is reprinted by the U.S. Pharmacopeial Convention Inc. (USP) as Volume III of the USP DI. 105 C MR 720.050(b) allows for the establishment of the Massachusetts Additional List of Interchangeable Drugs (Additional List), and provides the criteria upon which these drug products are approved. All prescriptions written by generic name can be interchanged if the drug is multi- source. To determine if a prescription written for a brand name drug product is interchangeable in Massachusetts:

1. Look up the drug product by the brand name in the index or by generic name in the "Approved Drug Products with Therapeutic Equivalence Evaluations" ("Orange Book"). The drug products are arranged alphabetically.
2. Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product in the "Orange Book".
3. If the same drug product, dosage form and strength has been assigned an "A" rating by FDA and is not listed on the Exception List contained within 105 CMR 720.050, the drug product is interchangeable.
4. If the drug product is not listed in the "Orange Book", refer to 105 CMR 720.050(b), the Massachusetts Additional List of Interchangeable Drugs (Additional List).
5. Look up the drug product by the generic name in the Additional List. The drug products are arranged alphabetically.
6. Compare the dosage form and strength of the drug product prescribed with the dosage form and strength of the same drug product listed on the Additional List.
7. If the same drug product, dosage form and strength are listed, the d rug p ro d uc t is interchangeable. Copies of the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements ("Orange Book") are available from the: U.S. Food and Drug Administration Department of Health and Human Services Government Printing Office Washington, D.C. 20402-9371 OPC 6768 (202) 783-3238 and www.fda.gov/cder/drug

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued Copies of the USP DI (third volume of USP DI is the "Orange Book") are available from: The United States Pharmacopeial Convention, Inc.,

12601 Twinbrook Parkway

Rockville, MD 20852

(301) 881-0666 Copies of the Massachusetts Additional List of Interchangeable Drug Products (document number 105 CMR 720.000) are available from: The State House Bookstore

Room 116

Boston, MA 02133

(617) 727-2834 and www.magnet.state.ma.us/dph/dcp/Drug Formulary/Drug Interchange

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued TABLE OF CONTENTS Foreword Introduction Drug Product Problem Reporting Instructions Exception List Format of the Additional List NDA, ANDA, Applicant (name) Changes Abbreviations Massachusetts Additional List of Interchangeable Drugs

(Alphabetical list of Official (Generic) Drug Names)

Partial Proprietary Brand Cross-reference FOREWORD The Massachusetts List of Interchangeable Drugs, is prepared by the Drug Formulary Commission (DFC) and the Department of Public Health. The DFC is comprised of nine men and women appointed by the Governor for the express purpose of developing a list of those drug products that are safely interchangeable -- that is, equivalent to each other in all significant respects. The DFC was established by M.G.L. c. 17, § 13. This law was enacted with the intent of saving money for consumers of prescription drugs, since drug products that are marketed under trademark or proprietary names are often available in the generic forms from competing manufacturers at substantially lower prices. M.G.L. c. 112, § 12D mandates prescription forms that allow practitioners to prescribe interchangeable drug products by simply signing the signature line. If a practitioner determines that a brand name drug product should be dispensed, he/she must sign the signature line and write the words "no substitution" in his/her own handwriting in the space provided below the signature line. The regulations call for the automatic adoption of "A" rated drug products listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements (commonly referred to as the "Orange Book") as published by the U.S. Food and Drug Administration, Department of Healthand Human Services, plus a list of additional drug products, the Massachusetts Additional List of Interchangeable Drugs ("Additional List"), individually reviewed and approved by the DFC and the Department. The regulations provide the criteria up on which the drug products listed on the Additional List are approved fo r interchange. The regulations also provide the DFC and the Department with the authority to review any "A" rated drug product listed in the "Orange Book" o r drug product approved for interchange on the Additional List and delete it from the list of interchangeable drug products if deemed appropriate. Drug products assigned an "A" rating by FDA which are deleted from the Massachusetts List are placed on the Exception List. Drug products listed on the Additional List which are subsequently deleted are removed from the Additional List. Of the many factors considered by the Commission in determining which drugs to include on the List, equivalent safety and effectiveness are paramount. The Commission reviews evidence on bioequivalence and pharmaceutical equivalence and includes on the List only those drug products determined to be fully interchangeable and whose manufacturers are approved by the U.S. Food and Drug Administration. Practitioners may prescribe any drug that appears on the List with confidence that it is as safe and effective as its brand name counterpart. The efforts of the Commission in the assessment and evaluation of data and the preparation of the List are to be commended. The Department presents the Massachusetts List of Interchangeable Drugs with pride and with confidence that the List will greatly b e ne fit c o nsumers throughout the Commonwealth.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.220 continued

720.220: continued INTRODUCTION INTERCHANGEABLE (GENERIC) DRUG LAW In 1976 the Massachusetts Legislature passed an Act Further Regulating the Establishment of a Formula ry o f Inte rchangeable Drug Products (St. 1976, c. 470, § 13), commonly known as the Generic Drug Law. This law, enacted to promote and regulate the use of generic drugs, created the Drug Formulary Commission to develop a list of interchangeable drug products and also required the use of a standard prescription form to encourage practitioners to prescribe generic drugs. PRESCRIPTION FORM M.G.L. c. 112, § 12D mandates prescription forms with one signature line. If the prescriber signs the prescription form and writes the words "no substitution" in his/her own handwriting in the space provided below the signature line, the pharmacist must fill the prescription exactly as indicated, with no interchange permitted. However, if the prescriber signs the prescription and does not write "no substitution" under his/her signature, the pharmacist is legally required to dispense a less expensive, equivalent interchangeable drug product listed in the Massachusetts List of Interchangeable Drugs if one is reasonably available. M ASSACHUSETTS LIST OF INTERCHANGEABLE DRUGS The Massachusetts List of Interchangeable Drugs (MLID) consists of the "A" rated drug products listed in the "Approved Drug Products with Therapeutic Equivalence Evaluations" and its supplements as published by the U.S. Food and Drug Administration, Department of Health and Human Services ("Orange Book") and the Massachusetts Additional List of Interchangeable Drugs (Additional List). The Additional List is deve lo p e d b y t he Drug Formulary Commission. The Commission determines drug products to be interchangeable only when they meet certain criteria: (a) the drug product is available from more than one source, with the same active ingredient in the same dosage form and strength; (b) its manufacturer is approved by the U.S. Food and Drug Administration (FDA); and (c) when essential to therapeutic outcome, the manufacturer of the drug has documented clinical evidence of bioequivalence. The Commission judges that all the drugs included on the MLID meet these standards and are bioequivalent, if essential, based on assessment and evaluatio n o f the U.S. Pharmacopeia and its supplements, other state and hospital formularies, listings of the U.S. Department of Health and Human Services of the FDA, and on the expertise of its members. The List does not include: (a) drugs that are protected by patent rights or available from only one source; (b) many controlled-release and enteric coated drug products since they may not consistently deliver the same quantities of their active ingredients; (c) those drugs for which the Commission had any significant doubt about safe interchange between manufacturers; and (d) any drug for which bioequivalence is considered essential but for which bioequivalence has not been demonstrated or an appropriate standard for bioequivalence has not been established. Bioequivalence is determined to be necessary for a particular drug when bioinequivalence might result in therapeutic fa ilure or hazard to the patient. Bioequivalent drug products do not show a significant difference in the rate and extent of absorption when administered at the same dosage under similar conditions. Drugs that are equivalent in the extent to which they are absorbed into a patient's body that differ in the rate of absorption may be therapeutically equivalent -- having the same medical effect -- either because the rate of absorption is not essential to the attainment of effective body concentrations of the drug, or because the difference in the rate is otherwise considered medically insignificant. Bioequivalence is a primary

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.220 continued

720.220: continued consideration for those drug products with a narrow therapeutic/toxic dosage range (when variation in the rate or extent of absorption could have a critical effect) where careful determination of the correct dosage and monitoring ofthe patient is essential to safe and effective use. To determine for which drugs bioequivalence is essential, the Commission relies on expert medical testimony, studies done by the pharmaceutical industry, the knowledge and expertise of the individual members of the Commission, and advice from the FDA. All drug products manufactured by FDA approved firms are considered safe and effective for their intended use, even if the product has not been included in the MLID. A practitioner may begin a patient's therapy with a drug product from any manufacturer who has beenapproved by the FDA, even though interchange of the drug once the dosage has been calculated for the individual is not advised. Several generic drug products are manufactured under the same new drug application (NDA) as the brand name drug products. According to section 1.6 of the Orange Book, drug products with the same NDA are therapeutically equivalent. Massachusetts regulations allow the interchange of these products. Distributors or repackagers of drug products manufactured under the same NDA as the brand name product are not identified in the Orange Book. Pharmacists who may not be able to determine if drug products are interchangeable should contact the manufacturers, distributors or repackagers. In addition the Department maintains an unofficial list of these products. Information relative to the Interchangeable (Ge neric) Drug Law may be obtained from the Department of Public Health, Division of Food and Drugs, 305 South Street, Jamaica Plain, MA 02130, telephone number (617) 727-2670, and fromthe Boards ofRegistration in Medicine, Dentistry and Pharmacy. DRUG PRODUCT PROBLEM REPORTING INSTRUCTIONS Since 1971 the United States Pharmacopeia (USP), in cooperation with various professional associations and the Food and Drug Administration (FDA), has operated the Drug Product Problem Reporting Program. This program can be utilized by pharmacists, physicians, or consumers to report any product problems encountered when using drugs interchanged under the Massachusetts generic drug law. The program is product oriented, and patient identification not requested. Should you prefer to remain anonymous, so indicate to the USP and your name will be withheld from the manufacturer and the FDA. Your partic ip a tio n in reporting problems will help to ensure that the drug products prescribed and dispensed in Massachusetts are of continued high quality. Reports should be sent to The United States Pharmacopeial Convention, Inc., 12601 Twinbrook Parkway, Rockville, MD 20852, (301) 881-0666. The USP is an impartial, non-governmental organization concerned with drug standards and quality control. After USP receives a report, copies are forwarded to the FDA and to the manufacturer of the product involved. Either the FDA or the manufacturer may act to investigate or correct problems. EXCEPTION LIST Orange Book "A" rated drug products not approved for interchange. There are currently no products designated to be listed on the Exception List. ADDITIONAL LIST The Massachusetts Additional List of Int erchangeable Drugs (Additional List) has been printed in a format designed to be concise and understandable. Interchangeable drugs are listed alphabetically according to their official (chemical or generic) names, and separate sections in each listing show dosage forms, strengths, FDA approved manufacturers, and categories.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.220 continued

720.220: continued DRUG Drugs are listed in alphabetical order by their generic names and are printed in capital letters. Drug products containing more than one active ingredient (for example, CODEINE PHOSPHATE, GUAIFENESIN) are listed in the conventional order of ingredients. Only drug products grouped under single headings are to be interchanged. DOSAGE FORM Under the generic names are listed the various multisource dosage forms in which a drug product is available. Abbreviations used for dosage forms and approved manufacturers are found in the front of the Additional List. Only identical dosage forms and strengths of identical drugs are to be interchanged. STRENGTH The approved strengths of the drug products are listed under the heading "S t r ength(s)." The "strengths" must be read along with the "dosage forms" since any strength shown is available only for the dosage form directly to its left. Dosage strength is in metric units that are sometimes rounded off from apothecary measures, which may introduce slight variations in the strength of certain products. Single ingredient drug product strengths are separated by commas. Combination drug products have a sla sh separating the strengths of the individual ingredients. If more than one strength of a single component of a combination drug product is approved, they will be separated by commas. For example, the strength of a tablet of aspirin with codeine phosphate is "325mg / 15mg, 30mg, 60mg" which means that the combination is available with 325 milligrams of aspirin and 15, 30, or 60 milligrams of codeine pho sp ha te. Drug products with three or more components have their active ingredients listed individually in parentheses and have slashes separating the strengths of the individual ingredients. M ANUFACTURERS Next to the heading "Manufacturers" are all approved manufacturers for the drug product in that group, listed by three letter abbreviations in capital letters. (See list of manufacturer abbreviations in front of the Additional List.) Listed manufacturers have met all legal requirements, including compliance with the FDA Good Manufacturing Practices for the production of the drug product indicated. Approved manufacturers hold current new drug applications (NDAs) or abbreviated new drug applications (ANDAs) when required by law. NDA, ANDA APPLICANT (NAM E) CHANGES Because it is not practical to identify in the Massachusetts Additional List of Interchangeable Drugs (Additional List) each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, these transfers and name changes are identified in this section. In addition, the new manufacturers are listed in parenthesis beside the original manufacturer under the Manufacturers' Abbreviations section of the Additional List. Where only partial approved product lines are transferred between applicants, each approved product involved will appear with the manufacturer name change in the Additional List amendment. Previously listed name changes have been incorporated into the revised Manufacturers’ Abbreviations section. ABBREVIATIONS The following abbreviations are used in the Massachusetts List of Interchangeable Drugs.

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued DOSAGE FORMS aero aerosol ml millilite r a mp a mp ule oint ointment cap capsule ophth ophthalmic conc concentrate oral gran oral granules for e.c. enteric-coated reconstitution e lix e lixir oral powder oral powder for g gram reconstitution Hbr hydrobromide oral sol oral solution HCl hydrochloride pow powder HC hydrocortisone sol solution inhl inha la tio n SR sustained release inhl liq uid inha la tio n liq uid subl tab sublingual tablet inhl sol inhalation solution supp suppository inj inje c tio n susp suspension irr s o l irriga ting s o lutio n syr syrup I.U. international units tab tablet liq liq uid top aero topical aerosol lot lotion top swab topical swab mcg microgram U units mEq milliequivalents vag vaginal mg milligram MANUFACTURERS' ABBREVIATIONS 3MP 3M Pharmaceutical Inc AAA Alpha Therapeutic ARC Arcola Labs. ABB Abbott APC Arcum Pharmaceuticlal Corp. ABI Abic ARP Armenpharm ABL Able Laboratories ARM Armour Pharmaceuticals ACI ACIC Limited ASC Ascot Hospital Products ACP Advanced Care Prod. ASA Asta ADV Advanced Remedies ASP Astra Pharmaceuticals LP AGV Agvar Chemicals ATH Athena Neurosciences AKO Akorn BAK Baker Norton AKZ Akzona Inc. BAN Banner Pharmacaps ALC Alcon Labs BAP Barlan Pharmacal ALL Allergan Pharmaceuticals B/I Boehringer Ingelheim ALI Alliance Pharmaceutical B/M Boehringer Mannheim. Ther. Div ALP Alpharma BAR Barr Labs APP Alphapharm Party BAS Basel Pharmaceuticals ALT Altana BAT Bartor ALZ Alza Corp. B&L Bausch & Lomb ALR Alra Laboratories BAY Bayer Corp AMA Amaric BEA Beach Prod. AMB Ambix Labs B-D Becton,Dickinson & Co. ACC American Cyanamid Co. BED Bedford Laboratories AHP American Home Products BEL Bell ARL American Regent Labs. BDP Beta Derm Pharmaceuticals AME Amersham BER Berlex AMG Amgen BFA B.F. Asher AMI Amide Pharmaceuticals BHC B.H. Chemicals AMT American Therapeutics BID Biodevelopment ANA Anabolic BIO Bio Technology General ANB Anbex BIV Biovail ANC Angus Chemical BLA Blairex Laboratories ANE Anesta BLO Block Drug Co. AN G Angelini APO Apothecon APK Apothekernes APP American Pharmaceutical Partners

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued BLU Bluline BRL Blue Ridge Laboratories BOC Bock Pharmacal BOW Bowman Pharm. BMS Bristol Myers Squibb BRC Bracco Diagnostics BRD Bradley Pharm. BRA Braintree Laboratories BRI Bristol-Myers Prod. BTG BTG Pharmaceuticals BVL Ben-Venue Labs BYR Byron Chemical C&M C & M Pharmacal CAD Cadema Medical Products CAG Calgon Corp. CDC Carderm Capital C-P Chesebrough - Ponds C-W Cook - Waite C/C Chase Chemical CSL Chase Laboratories C/P Corvit Pharmaceuticals CAL Carlisle CAM Camall CAR Carnick Labs CTW CarterWallace CEN Century Pharmaceuticals CBV Cetus Ben Venue Therapeutics CHA Chamberlin Parenteral Corp. CHE Chelsea Laboratories CHM Chemed Corp. CVO Ciba Vision Ophthalmics CIR Circa Pharmaceuticals CJD Copanos, J.D. CLA Clay - Park CLO Clonmel Healthcare CMB C.M. Bundy CMC Consolidated Midland Corp. C/T Controlled Therapeutics CMP Carolina Medical Products CNC H.R. Cenci COL Colgate Palmolive COM Combe CON Connaught Laboratories COO Cooper Labs COP Copley Pharmaceutical CPG Consolidated Pharmacy Group CRE Creighton Products CUM Cumberland Swan CUR Curatex Pharmaceuticals CTL Central Pharmacal D&G Davis & Geck D/L DPT Laboratories D-R Del-Ray Laboratories Inc. DAN Danbury Pharmacal DAR Darby Group Companies DEL Dell DEP Deproco DER Dermik Laboratories DES Deseret Medical DEY Deylabs DHL DHL Laboratories DIA Dial Corp. DIS DMD DMG DOW DPT DPM DUR DUN DYN E/K EAT ECR ELA ELL EMP END EON ENQ EN Z ESR ERS ESI ESP ETH ETX ETK EVY EZC FAU FER FRT FRR FIS FLE FOR FOU FOY FRE G&W GAL GEI GEC GED GET GEP GEV GES GEZ GIL GLD GLW GLE GLO G/P GO L GRE GRI G/L GUA GYM GYN H-R Dista Duramed D M Graham Laboratories Dow Pharmaceutical Dupont Pharmaceuticals Dupont Merck Dura Pharmaceuticals Dunhall Dynapharm Eastman Kodak Eaton Medical Corp. ECR Pharmaceuticals Elan Pharmaceuticals Ellis Pharmaceuticals EM Pharma Endo Eon Laboratories Enquay Pharm Enzon Elkins- Sinn/AH Robins Ersana ESI Lederle Generics ESI Pharmacal Ethicon Inc. Ethex Ethitek Pharmaceuticals Everylife E Z EM Co. Faulding Pharm. Co. Ferndale Ferrante Ferring Labs Fisons Fleming & C o. Forest Fougera Foy Fresenius G & W Galderma Geigy Gencon Genderm Genentech Genpharm Geneva Gensia Sicor Pharmaceuticals Inc Genzyme Gilbert Laboratories Glades GlaxoWellcome Glenwood Global Pharm. Golden Pharms. Goldine Greenstone Griffen,KW Gruppo Lepetit Guardian GYMA Laboratories Gynopharm Holland-Rantos

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued HAL Halsey Labs LEO Leo Pharms HAM Hamilton Pharmaceuticals LIF Life Labs HAN Hnford GC LIL Lilly HEA Heather LIP Liposome HEN Heran Pharmaceutical LIQ Liquipharm HEX Hexcel Chemical Products LNK LNK International HER Hermal Pharmaceutical LOC Loch Pharmaceuticals HIC Hickam LO R Lorex H/D Hill Dermaceuticals LOT Lotus Biochemical HIR Hirsch Industries LPI LPI Holding HIT Hi Tech Pharma LUI Luitpold HTP High Technology Pharmacal LUS Lek USA Inc. HLC Halocarbon LYN LYNE Laboratories HCC Hoechst Celanese Corp. M/P Mallinckrodt Pharmaceutical. HMR Hoechst Marion Roussell MAY Mayrand HOE Hoechst-Rousel MAT Matrix Labs HOR Horus Therapeutics MCG Mcgaw HO Y Hoyt MCN McNeil Consumer Products HUD Hudson Pharmaceuticals MDP MD Pharmaceuticals HUN Huntington MEA Mead Johnson HYB Hybritec Inc. MJN Mead Johnson Nutritionals HYG Hygenics M/R Medco Research HYR Hyrex MVA Medeva IMM Immunex MEP Medics Pharmaceuticals IMP IMP Inc. MPI Medi Physics, Inc. ICN ICN Pharmaceuticals MAG Mepha AG IMS International Medication MER Mericon INP Interpharm MET Metronic INV Invamed, Inc. MGI MGI Pharma INW Inwood Labs MID Midway Medical ICC Interchem Corp. MIK Mikart Laboratories ILC International Latex Corp. MIS Mission Pharmacol ING Ingram Pharmaceutical MJP MJ Pharmaceuticals INH Inhalon MKL Moore Kirk Labs IOL Iolab MLI Marchar Laboratories IOM Iomed MLP Miller Pharmacal IPR IPR Pharm MLX Milex IVA IVAX MMD Marion Merrell Dow J&J Johnson & Johnson MOR Morton Grove JAC Jacobus MCK Merck & Co. JAN Janssen Pharmaceuticals MSM Marsam JER Jerome Stevens Labs MSL Marshall Pharmacal JRW Johnson RW MTC Martec JON Jones Pharma Inc MOV Mova KAL Kalapharm MUR Muro KBP Kabi Pharmacia MUT Mutual Pharmaceuticals KEE Keene MYL Mylan Pharmaceuticals KED Kendall NEP Nephron Pharmaceuticals Inc KEN Kenwood NEU Neutrogena KIN King Pharmaceuticals NOR Norbrook Laboratories KIR Kirkman Sales N/W Norton Waterford KNO Knoll N/N Novo Nordisk KPI Key Pharmaceuticals NEW Newtron Pharmaceuticals KVP KV Pharmaceutical Co. NHN Norton HN L/F Labs Fournier NOV Novocol L/A Laboratories Atral NVP Novopharm Ltd. LAF Lafayette Pharms NUM Numark LAN Lannett NYC Nycomed LED Lederle NYL Nylos Trading LEI Leiras ORI Organon, Inc. LEK Lek Ljubliana OCL Oclassen LEM Lemmon OHM OHM Laboratories

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued OMD Ohmeda Pharmaceutical OSA On Site Azla ODC Ormont Drug & Chemical OPC Ortho Pharmaceuticals OPT Optopic Laboratories Corp. ORG Organics OAP Otsuka America Pharmaceutical PAK Pal-Pak PAL Palisades P/D Parke Davis P/I Plantex/Ikpharm P/K Purepac-Kalipharma P/P Parmed Pharmaceuticals PAC Paco Research PAD Paddock Labs PHD Pharmaderm PAN Panray PAR Par PNL Parnell PER Perrigo PCE Pharmachemie PHC Pharmics PHK Pharmakinetics Labs PHM Pharmeral PHO Phoenix Labs PHS Pharma Serve PHT Pharmaton PFF Pfeiffer PFI Pfizer P/U Pharmacia & Upjohn P/A Pharmaceutical Association PIO Pioneer Pharmaceutical Inc. PPI Physicians Products Inc. PSA Pharmaceutical Specialist Assoc POH Pohl Boskamp POL Polymedia PGP Prographarm PRD Professional Disposables PRO Proter Laboratory PRI Private Formulations P&G Proctor & Gamble PRV Pharmavite PTK Pharma-Tek PUF Purdue Frederick PUR Purepac QUA Quantum Pharmics Ltd. QLT QLT PhototherapeuticsInc. RAN Ranbaxy Pharmaceuticals R/C Reckitt & Colman R&C Reed & Carnrick R/I Research Industries RXP Rexar Pharmacal RAC Rachelle Labs REN Ren-Pharm Internatl. Ltd. RHP Rhone - Poulenc RPR Rhone-Poulenc Rorer RAH Robins, A.H. REX Rexall/Sundown RIC Richlyn Labs ROC Roche Labs. RPF Roerig/Pfizer ROA Roaco RBP ROR ROS ROX ROY RPC RUG S-M S/W S/L SAK SAV SAN SCE SPI SCH S/P SWZ SZG SCI SCS SEA SER SEQ SHM SHI SID SIG SIX SKB SBH SOL SLV SOM SBM SDP STI STL STR STS STZ SUP SPP SUR SYN SYO TAB TAG TAK TAP TAR TAY TEC THE THK THA TIC TOP T/L TOR UDL UMD Roberts Pharmaceutical Rorer Ross Labs Roxane Labs Royce Laboratories Rosemont Pharmaceutical Corp. Rugby Labs Spencer-Mead Sanofi Winthrop Schmid Laboratories Sankyo Savage Labs/Altana Sandoz Scherer, R.P. Schein Pharmaceutical, Inc. Schering Corporation Schering/Plough Schwarz Pharma SchwarzGMBH ScinoPharm International SCS Pharmaceuticals Searle Serono Laboratories Sequus Pharmaceuticals Sherwood Medical Shionogi USA Sidmak Laboratories Sigma Tau Silarx Smith, Kline Beecham Sola Barnes Hind Solopak Laboratories Solvay Somerset Sorin Biomedics Sperti Drug Products Steifel Stanlabs Pharmaceutical Co. Star Pharmaceuticals Steris Laboratories Storz Ophthalmics Superpharm Suppositoria Survival Technology Syntex Syosset Labs Tablicaps Tag Pharmaceuticals Takeda Tap Holdings Taro Pharmaceutical Taylor Pharmaceuticals Technilab Theratech Therakos Thames Phamacol Co. Inc. Tican Pharmaceuticals Topiderm Torch Laboratories Torigian Lab UDL Laboratories Unimed

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued UPJ Upjohn USL Upsher-Smith Labs VAL Vale Chemical VAN Vangard VES Vestal VIC Vicks Pharmacy Products VIN Vintage VIR Viratek VIS Vistakon, Inc. VIV Vivan Pharmacal W-A Wyeth Ayerst W-C Warner-Chilcott WAW Warner Wellcome WRR Warrick Pharm WEP WE Pharmaceuticals WEN Wendt Laboratories WPP WES W-W W/L WBY WWT WAL WAR WAT WOC XTT YAM YOS ZCA ZGP West Point Pharma Westwood Squibb Pharmaceuticals West-Ward Wharton Labs Whitby Whiteworth Towne Wallace Labs Warner-Lambert Watson Laboratories Wockhardt Xttrium Laboratories Yamanouchi Yoshitomi Laboratories Zeneca Zenith Goldline Pharmaceuticals M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS

AM INOPHYLLINE, EPHEDRINE Hcl Dosage form(s): T ABLETS St rengt h(s): 130mg/25mg M anufact urers : ST L Category: OTC AMYL NITRITE Dosage form(s): INHALAT ION St rengt h(s): 0.3ml M anufacturers: GLW, CM C Category : PRE-38 ASPIRIN W/ CODEINE PHOSPHATE Dosage form(s): T ABLET St rengt h(s): 325mg/15mg, 30mg, 60mg M anufacturers: BAR, GLW, CHE, GEV, HAL, P/D, ZGP Category : PRE-38 ATROPINE SULFATE Dosage form(s): OPHTHALM IC SOLUTION Strength(s): 0.5%, 1%, 2% OPHTHALM IC OINTM ENT 0.5%, 1% M anufacturers: ALC, ALL, ESR, FOU, INV, M UR, B&L, STS, SUR Category : PRE-38 AT ROPINE SULFAT E COM POUND (AT ROPINE SULFAT E, SCOPOLAM INE HBr, HYOSCYAM INE SULFAT E, PHENOBARBIT AL) Dosage form(s): T ABLET St rengt h(s): 0.0194mg/0.0065mg/ 0 1037mg/16.2mg M anufacturers: ALL, CHE, M /P, M AY, T AY, RAH, WES Cat egory : D ESI BENZOCAINE, ANTIPYRINE Dosage form(s): OTIC SOLUTION Strength(s): 1.4%, 5.4% M anufacturers: AM B, W-A, CLA, RPC, S-M , THA Category : PRE-38 BENZOYL PEROXIDE Dosage form(s): GELStrength(s): 2.5%, 5%, 10% M anufacturers: BM S, CLA, GAL, ST I, SYO, VIC, WES Category : OTC BENZTHIAZIDE Dosage form(s): T ABLET St rengt h(s): 50mg M anufacturers: GEV, PFI, RAH, Category: B BROM PHENIRAM INE M ALEATE, DEXTROM ETHORPHAN HBr, PSEUDOEPHEDRINE HCl Dosage form(s): SYRUP St rengt h(s): 2mg/10mg/30mg/5ml M anufacturers: RAH, RPC Category: OTC

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS BROM PHENIRAM INE M ALEATE, PHENYLPROPANOLAM INE HCl, PHENYLEPHRINE, GUAIFENESIN COM BINATION Dosage form(s): SYRUP St rengt h(s): 4mg/5mg/5mg/100mg/5ml M anufacturers: HAL, LIF, RAH, RPC, Category: OTC CAFFEINE AND SODIUM BENZOATE Dosage form(s): INJECT ION St rengt h(s): 250mg/ml M anufacturers: TAY Category : PRE-38 CALCIUM GLUCONATE Dosage form(s): INJECTION Strength(s): 10% M anufacturers: ARL, APC, APP, CM C, CEN, BAY, ESR, GEN, HYR, KIR, LAN, LIL, M /P, P/D, RIC, STL, P/U , Category : PRE-38 CARBINOXAM INE M ALEATE, PSEUDOEPHEDRINE HCl, DEXTROM ETHORPHAN HBr Dosage form(s): DROPS St rengt h(s): 2mg/25mg/4mg/ml SYRUP 4mg/60mg/15mg/5ml M anufacturers: ALP, ROS Category : PRE-38 CHLORAL HYDRATE Dosage form(s): CAPSULE St rengt h(s): 500mg SYRUP 250mg/5ml, 500mg/5ml M anufacturers: BM S, C/C, ALP, PHC, PUR, ROX, SCE, , Z EN Category : PRE-38 CHLORDIAZEPOXIDE W/ CLIDINIUM BROM IDE Dosage form(s): CAPSULE St rengt h(s): 5mg/2.5mg M anufacturers: BAR, CHE, EON, GEV, HAL, ROC, LEM , PAR, QUA, ZGP Category: DESI CHLOROTHIAZIDE W/ RESERPINE Dosage form(s): T ABLET St rengt h(s): 250mg/0.125mg, 500mg/0.125mg M anufacturers: M CK, M YL, Category: B CHLORPHENIRAMINE MALEATE Dosage form(s): T ABLET St rengt h(s): 4mg, 8mg, 12mg SYRUP 2mg/5ml M anufact urers : LA N , SCH Category : OTC CHOLINE M AGNESIUM T RISALICYLAT E (CHOLINE SALICYLAT E, M AGNESIUM SALICYLAT E) Dosage form(s): TABLET Strength(s): 500mg (=293mg/362mg), 750mg (=440mg/544mg), 1000mg (=587mg/725mg) M anufact urers : P U F , SID Category : PRE-38 CODEINE PHOSPHATE Dosage form(s): INJECT ION St rengt h(s): 15mg, 30mg, 60mg/ml M anufacturers: ESR, KNO, STL, W-A Category : PRE-38 CODEINE PHOSPHATE /GUAIFENESIN LIQUID Dosage form(s): LIQUID St rengt h(s): 10mg/100mg/5ml M anufacturers: RAH, HAL Category : PRE-38 CYANOCOBALAM IN Dosage form(s): TABLET Strength(s): 10mcg, 25mcg, CAPSULE 50mcg, 100mcg, 250mcg M anufacturers: APP, BER, BM S, STS, DEL, ESR, INV, LEM , LIL, M M D, M CK, ALP, ORI, P/D, SAV, SOL, P/U, W-A Category: OTC

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS CYCLANDELATE Dosage form(s): M anufacturers: Category: CAPSULE St rengt h(s): 200mg/400mg CHE, GEV, DAN, FOR, INW, W-A, LAN, LEM , M DP, PAR, PIO, ZGP DESI DEXAM ETHASONE Dosage form(s): M anufact urers : Category : T ABLET St rengt h(s):0.25mg, 0.5mg, 0.75mg, 1.5mg, 4mg G EV, D A N , M CK , M YL, O RI, PA R, PRI, RIC, SLV, RO X , , U SL B DIETHYLPROPION HCl Dosage form(s): M anufacturers: Category : T ABLET St rengt h(s): 25mg SUST AINED RELEASE T ABLET 75mg CAM , , LEM , M M D, M DP, 3M P B DIETHYLSTILBESTROL Dosage form(s): M anufacturers: Category : T ABLET St rengt h(s): 0.1mg, 0.5mg, 1.5mg VAGINAL SUPPOSIT ORIES BM S, LIL B DIGOXIN Dosage form(s): M anufacturers: Category : T ABLET St rengt h(s): 0.125mg, 0.25mg, 0.5 mg GLW, AM I PRE-38 DIGOXIN Dosage form(s): M anufacturers: Category : INJECT ION St rengt h(s): 0.25mg/ml, 0.5mg/2ml GLW, ESR, EON, W-A PRE-38 DIMENHYDRINATE Dosage form(s): M anufacturers: Category : T ABLET St rengt h(s): 50mg ANA, STS, CHE, GEV, ESR, LEM , SEA, , W-A OTC DIPHENHYDRAM INE HCl Dosage form(s): M anufacturers: Category : CAPSULE St rengt h(s): 25mg, 50mg ELIXIR 12.5mg/5ml HAL, ICN, P/D OTC DISULFIRAM Dosage form(s): M anufacturers: Category : T ABLET St rengt h(s): 250mg, 500mg W-A, DAN B EPINEPHRINE HCl Dosage form(s): M anufacturers: Category : INJECTION Strength(s): 0.01%, 0.1% OPHTHALM IC SOLUTION 0.1%, 0.25%, 0.5%, 1%, 2% ABB, ALC, ALL, ARL, ESR,IM S, INV, LAN, P/D, W-A PRE-38 EST ROGENS, EST ERIFIED Dosage form(s): M anufact urers : Category: T ABLET St rengt h(s): 0.3mg, 0.625mg, 1.25mg, 2.5mg BM S, PRI, SLV, SKB, SYN B ETHAVERINE HCl Dosage form(s): M anufacturers: Category : CAPSULE St rengt h(s): 100mg T ABLET BFA, KEN, LEM , M EP PRE-38 ETHINYL ESTRADIOL Dosage form(s): M anufacturers: Category : T ABLET St rengt h(s): 0.02mg, 0.05mg ORI, SCH, P/U B

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS FLUOXYM ESTERONE Dosage form(s): T ABLET St rengt h(s): 2mg, 5mg, 10mg M anufacturers: BM S, RPC, P/U Category : B GLYBURIDE Dosage form(s): T ABLET St rengt h(s): 1.25mg, 2.5mg, 5mg M anufacturers: HOE, P/U Category : B HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE Dosage form(s): T ABLET St rengt h(s): 25mg/15mg/0.1mg M anufacturers: DAN, GEI, LEM Category : B HYDROCHLOROTHIAZIDE W/ RESERPINE Dosage form(s): TABLET Strength(s): 25mg/0.125mg, 50mg/0.125mg, 25mg/0.1mg, 50mg/0.1mg M anufacturers: KNO, CAM , GEI, GEV, DAN, LEM , M CK, PUR, ZGP Category : B HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAM INE Dosage form(s): SYRUP St rengt h(s): 5mg/25mg/5ml M anufacturers: DPT, ALP, RPC Category : OTHER HYDROCORTISONE, IODOCHLORHYDROXYQUIN Dosage form(s): CREAM Strength(s): 0.5%, 1% / 3% OINTM ENT M anufacturers: AM B, ALT, CLA, DER, BAY, DUR, GEI, LEM , ALP, SLV, THA, Category: DESI HYDROFLUM ETHIAZIDE, RESERPINE Dosage form(s): T ABLET St rengt h(s): 25mg, 50mg/0.125mg M anufacturers: APO, RPC, ZGP Category: B HYDROQUINONE 4% CREAM Dosage form(s): TOPICAL CREAM Strength(s): 4% M anufacturers: ICN, ETX Category : PRE-62 HYDROQUINONE CREAM 4% Dosage form(s): CREAM Strength(s): 4% M anufacturers: ICN; GLD Category : PRE-1962 H YD RO Q U IN O N E 4% CREA M w it h SUN CREEN S Dosage form(s): TOPICAL CREAM Strength(s): 4% M anufacturers: ICN, ETX Category : PRE-62 HYDROQUINONE CREAM 4% wit h SUNCREEN Dosage form(s): CREAM Strength(s): 4% M anufacturers: ICN; GLD Category : PRE-1962 HYDROQUINONE TOPICAL SOLUTION Dosage form(s): TOPICAL SOLUTION Strength(s): 3% M anufacturers: NEU, GLD Category : PRE-38 8/31/01 105 CMR - 4118.4118

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued NON- TEXT PAGE 8/31/01 105 CMR - 4118.1

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS ISOSORBIDE DINITRATE Dosage form(s): SUST AINED RELEASE CAPSULE St rengt h(s): 40mg M anufacturers: ASC, GEV, FOR, W-A, SUP Category: B ISOXSUPRINE HCl Dosage form(s): T ABLET St rengt h(s): 10mg, 20mg M anufact urers : G EV, M EA Category : PRE-38 L-HYOSCYAMINE SULFATE Dosage form(s): T ABLET St rengt h(s): 0.125mg M anufacturers: BFA, GLW, SWZ Category : PRE-38 LEVODOPA Dosage form(s): T ABLET St rengt h(s): 250mg, 500mg CAPSULE 100, 250, 500mg M anufacturers: ROC, P&G Category : B M AGNESIUM SALICYLATE Dosage form(s): T ABLET St rengt h(s): 600mg M anufacturers: BFA, END, RBP, M LP, , Category : OTHER M AGNESIUM SULFATE Dosage form(s): INJECTION Strength(s): 10%, 12.5%, 50% M anufacturers: ABB, APP, ARL, CM C, ESR, IM S, LIL Category : PRE-38 M AZINDOL Dosage form(s): T ABLET St rengt h(s): 1mg M anufact urers : SA N , W-A Category : B M EPHOBARBITAL Dosage form(s): T ABLET St rengt h(s): 32mg, 100mg, 200mg M anufacturers: BOW, ICN, S/W Category : PRE-38 METHENAMINE MANDELATE Dosage form(s): SUSPENSION St rengt h(s): 0.25, 0.5g/5ml TABLET 0.25g, 0.5g, 1g ENTERIC COATED TABLET 0.25g, 0.5g, 1g M anufacturers: GEV, HEA, ALP, P/D, RIC, SLV, TAB Category : PRE-38 M ET HENAM INE COM BINAT ION (M ET HENAM INE, PHENYLSALICYLAT E, AT ROPINE SULFAT E, HYOSCYAM INE, BENZ OIC ACID, M ET HYLENE BLUE) Dosage form(s): T ABLET St rengt h(s): 40.8mg/18mg/0.03mg/ 0.03mg/4.5mg/5.4mg Manufacturers: CHE, LEM, , S-M, STR Category: DESI M ETHYLENE BLUE Dosage form(s): INJECTION Strength(s): 1% T ABLET M anufact urers : A RL, CM C, ESR, T A Y, Category : PRE-38 8/16/02 105 CMR - 4119

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS M ETHYLTESTOSTERONE Dosage form(s): CAPSULE St rengt h(s): 10mg SUBL. T ABLET 10mg, 25mg M anufacturers: DAN, INW, LAN, PUR, SCH Category: B M ORPHINE SULFATE Dosage form(s): SUST AINED RELEASE T ABLET St rengt h(s): 30mg, 60mg, 100mg M anufacturers: PUF, ROX Category: B NEOSTIGMINE METHYLSULFATE Dosage form(s): INJECTION Strength(s): 1-1000, 1-2000, 1-4000 M anufacturers: CM C, ESR, LAN, S-M , Category : PRE-38 NITROGLYCERIN Dosage form(s): SUBLINGUAL T ABLET St rengt h(s): 0.3mg, 0.4mg, 0.6mg M anufacturers: P/D ET X Category : PRE-38 NORTRIPTYLINE HCl Dosage form(s): CAPSULE St rengt h(s): 10mg, 25mg M anufact urers : LIL, SAN Category: B NYLIDRIN Dosage form(s): T ABLET St rengt h(s): 6mg, 12mg M anufacturers: GEV, C/P, DAN, ROR, ZGP Category: DESI OPIUM T INCT URE, DEODORIZ ED Dosage form(s): LIQUID Strength(s): 10% OPIUM M anufacturers: HAL, LIL Category : PRE-38 PAPAVERINE HCl (NON-SUST AINED RELEASE) Dosage form(s): INJECT ION St rengt h(s): 30mg/ml CAPSULE 75mg, 150mg, 300mg T ABLET 30mg, 60mg, 100mg, 150mg, 200mg, 300mg M anufacturers: CHE, CM C, GEV, DAN, HAL, HEA, LAN, LEM , M M D, M YL, PUR, REN, SLV, VAN, EON, ZGP Category : PRE-38 PARALDEHYDE Dosage form(s): LIQUID Strength(s): 100% INJECTION M anufact urers : CM C, ESR, Category : PRE-38 PAREGORIC Dosage form(s): LIQUID St rengt h(s): 2mg M ORPHINE EQUIV./5ml Manufacturers: APC, BOW, HAL, LAN, LIL, ALP, P/D, PUR, ROX, RPC, STL Category : OTC PENICILLIN G BENZATHINE Dosage form(s): INJECT ION St rengt h(s): 600, 000 UNIT S/ml M anufacturers: PFI, W-A Category : B PENTAERYTHRITOL TETRANITRATE Dosage form(s): TABLET Strength(s): 10, 20 SUST AINED ACT ION T ABLET 80mg M anufacturers: COO, GEV, DAN, INW, KIR, M ER, P/D, PUR, STA, S-M , ZGP Category: DESI 8/16/02 105 CMR - 4120

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS PHENAZOPYRIDINE HCl Dosage form(s): T ABLET St rengt h(s): 100mg, 200mg M anufacturers: AM I, BAR, COP, C-P, LAN, P/D, QUA, RIC, S-M , TAB, VAN, Category : PRE-38 PHENOBARBITAL Dosage form(s): ELIXIR St rengt h(s): 20mg/5ml T ABLET 15mg, 16mg, 30mg, 32mg, 60mg, 65mg, 100mg M anufacturers: APC, BAR, BOW, GEV, C/P, DAN, HAL, ICN, INW, LAN, LED, LEM , LIL, M M D, ALP, P/D, PUR, REX, ROX, RUG, STL, STA, TAB, EON, W-W, S/W, W-A, ZGP Category : PRE-38 PHENYLEPHRINE HCl Dosage form(s): SOLUTION Strength(s): 0.25%, 1% OPHTHALM IC SOLUTION 0.12, 2.5, 10% M anufacturers: AKO, ALC, ALL, ALP, M UR, B&L, PUF, RPC, ST S, S/W Category : PRE-38 PHENYLPROPANOLAM INE HCl, PHENYLEPHRINE HCl, PHENYLTOLOXAM INE CITRATE, CHLORPHENIRAM INE M ALEATE Dosage form(s): PEDIAT RIC DROPS St rengt h(s): 5mg/1.25mg/2mg/0.5mg/ml PEDIAT RIC SYRUP 5mg/1.25mg/2mg/0.5mg/5ml M anufacturers: ALP, APO Category : PRE-38 PHYTONADIONE Dosage form(s): INJECT ION St rengt h(s): 2mg, 10mg/ml M anufacturers: ABB, ROC, IM S, M CK, SKB Category: B PILOCARPINE HCl Dosage form(s): OPHTHALM IC SOLUTION Strength(s): 0.25%, 0.5%, 1%, 2%, 3%, 4%, 6%, 8% Manufacturers: ALC, CVO, W-A, OPT, B&L, PRO, STS Category : PRE-38 PIPERAZINE CITRATE Dosage form(s): SYRUP St rengt h(s): 500mg/5ml T ABLET 250mg, 500mg M anufacturers: BLU,ALP, GLW, LAN, SLV, S/W Category : PRE-38 POTASSIUM GLUCONATE Dosage form(s): LIQUID St rengt h(s): 20mEq/15ml M anufacturers: ALP, CM C, GEV, LAN, LED, , RAH, ROX, RPC, S-M , Category : B POTASSIUM IODIDE Dosage form(s): LIQUID Strength(s): SATURATED SOLUTION M anufact urers : A LP , CM C, G EN , G EV, P/R, RO X , RP C, ST L, , U SL Category : PRE-38 PREDNISOLONE ACETATE Dosage form(s): INJECT ION St rengt h(s): 25, 50, 100mg/ml M anufacturers: ALC, ALL, CTL, STS, LEM , B&L, SCH Category : B PREDNISOLONE TEBUTATE Dosage form(s): INJECT ION St rengt h(s): 20mg/ml M anufacturers: ALP, FOY, RBP, M CK Category : B PROBENECID W/ COLCHICINE Dosage form(s): T ABLET St rengt h(s): 500mg/0.5mg M anufacturers: DAN, LEM , M CK, RIC, ZGP Category : B 8/16/02 105 CMR - 4121

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS PROM ETHAZINE HCl Dosage form(s): T ABLET St rengt h(s): 12.5mg, 25mg, 50mg M anufacturers: ALL, ALT, ALP, DAN, ESR, GEV, KNO, KVN, LEM , LIF, M SM , RPC, S/W, W-A Category: B PROPYLTHIOURACIL Dosage form(s): T ABLET St rengt h(s): 50mg M anufacturers: ANA, KNO, CHE, DAN, LIL, HAL, LAN, LED, P/D, PUR, RIC, T AB, W-W, Z EN Category : B PSEUDOEPHEDRINE HCl Dosage form(s): LIQUID St rengt h(s): 30mg/5ml T ABLET 30mg, 60mg SUST AINED RELEASE CAPSULE 120mg M anufacturers: ALP, BOW, GLW, CEN, CHE, GEV, DAN, HAL, RBP, LEM , M M D, PAR, ROX, SLV, SUP Category : OTC PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE Dosage form(s): T ABLET St rengt h(s): 60mg/4mg M anufacturers: BER, GLW, ROR, SCH, SKB Category : OTC PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE Dosage form(s): SUST AINED RELEASE T ABLET St rengt h(s): 120mg/6mg M anufacturers: COP, GEV, SCH Category : OTC QUININE SULFATE Dosage form(s): T ABLET St rengt h(s): 260mg M anufacturers: CHE, GEV, M M D Category : PRE-38 RAUWOLFIA SERPENTINA Dosage form(s): T ABLET St rengt h(s): 50mg, 100mg M anufacturers: BOW, CM B, GEV, DAN, FER, HAL, ICN, KIR, PAN, PPI, PRI, BM S, SLV, RIC, TAB, VAL, Z EN Category : B RESERPINE Dosage form(s): T ABLET St rengt h(s): 0.1mg, 0.25mg, 0.5mg, 1.0mg INJECTION M anufacturers: BEL, BM S, BOW, CM B, GEV, DAN, FER, GEI, GEN, HAL, ICN, , KIR, LAN, LEM , LIL, M K L, M YL, PA N , PRV, PRI, PU R, SLV, REX , RIC, RO X , ST L, T A B, P/U , VAL, Z EN Category: B SALSALATE Dosage form(s): T ABLET St rengt h(s): 500mg, 750mg M anufact urers : G EV, 3M P , SID Category : Pre-38 SODIUM FLUORIDE Dosage form(s): TABLET Strength(s): 0.55mg, 1.1mg, 2.2mg (NaF) DROPS 0.125mg (F-)/DROP CHEWABLE TABLET 0.55mg, 1.1mg, 2.2mg (NaF) M anufacturers: ABL, KNO, BOW, CHE, CM C, COP, C-P, GEN, HOY, KIR, RIC, RUG, ST L, Category : PRE-38 SULFAM ETHOXAZOLE, PHENAZOPYRIDINE HCl Dosage form(s): T ABLET St rengt h(s): 500/100mg M anufacturers: COP, RIC Category: DESI SULFASALAZINE Dosage form(s): ENT ERIC COAT ED T ABLETS St rengt h(s): 500mg M anufacturers: DAN, LED, LEM , M UT, KBP, ROW, SUP, VIP Category : B 8/16/02 105 CMR - 4122

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued M ASSACHUSETTS ADDITIONAL LIST OF INTERCHANGEABLE DRUGS SULFISOXAZOLE PHENAZOPYRIDINE HCl Dosage form(s): T ABLET St rengt h(s): 500/50mg M anufacturers: COP, KAY, ROC, ROX, SLV, S-M , STN, VAN, Category: DESI TERBUTALINE SULFATE Dosage form(s): T ABLET St rengt h(s): 2.5mg, 5mg M anufacturers: GEI, M M D Category: B TESTOSTERONE Dosage form(s): INJECT ION St rengt h(s): 25mg/ml, 50mg/ml, 100mg/ml M anufacturers: BAT, STS,RBP, LIL, M AY Category : PRE-38 TETRACAINE HCl Dosage form(s): OPHTHALM IC SOLUTION Strength(s): 0.5% M anufacturers: ALC, GEN, B&L, S-M , S/W Category : PRE-38 T HEOPHYLLINE (NON-SUST AINED RELEASE) Dosage form(s): CAPSULE St rengt h(s): 100mg, 200mg T ABLET 100, 125, 200, 225, 250mg M anufacturers: ALP, BEL, BER, CNC, CTL, FER, HAL, KNO, LAN, LIF, M M D, PAN, P/A, RIC, 3M P, ROR, ROX, RPC, SEA, Category: B THEOPHYLLINE, GUAIFENESIN Dosage form(s): ELIXIR St rengt h(s): 150mg/90mg/15ml LIQUID M anufacturers: M EA, RPC Category : PRE-38 T HEOPHYLLINE, POT ASSIUM IODIDE (T HEOPHYLLINE, POT ASSIUM IODIDE, ALCOHOL) Dosage form(s): ELIXIR St rengt h(s): 80mg/130mg/10%/15ml M anufacturers: FOR, ALP, RPC Category : PRE-38 THYROGLOBULIN Dosage form(s): T ABLET St rengt h(s): 65mg M anufacturers: RIC, P/D, W-L Category : B TRIAMCINOLONE DIACETATE Dosage form(s): INJECT ION St rengt h(s): 25mg, 40mg/ml M anufacturers: BM S, LED, LEM , ST S Category : B TRICHLORM ETHIAZIDE, RESERPINE Dosage form(s): T ABLET St rengt h(s): 4mg/0.1mg M anufact urers : M M D , SCH Category : B TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl Dosage form(s): T ABLET St rengt h(s): 2.5mg/60mg SYRUP 1.25mg/30mg/5ml M anufacturers: GLW, ALP, CHE, CNC, GEV, HAL, ICN, LED, LEM , LIF, NEW, B&L, PRI, PUR, ROX, SLV, SUP, VAN, Z EN Category : OTC TRYPSIN, BALSAM PERU, CASTOR OIL Dosage form(s): TOPICAL AEROSOL Strength(s): 0.1mg/72.5mg/650mg IN EACH 0.82CC SPRAY M anufacturers: COP, HIC Category : PRE-38 8/16/02 105 CMR - 4123

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued PARTIAL PROPRIETARY BRAND CROSS-REFERENCE Generically equivalent drug products in the same strength and dosage form listed in theAdditional List are interchangeable if their respective manufacturers are listed for that product. This partial cross- reference section does not attempt to list all brand names which are approved for interchange. For most products only one, usually the innovator or most commonly prescribed brand, is listed below for quick reference purposes. See page 4105 for precise instructions for determining the interchangeability of drug products. BRAND SEE (AT ROPINE SULFAT E, HYOSCINE HBr, HYOSCYAM INE HBr, PHENOBARBIT AL) (T HEOPHYLLINE, POT ASSIUM IODIDE, ALCOHOL) ACTIFED ............................................................TRIPROLIDINE HCl, PSEUDOEPHEDRINE HCl ANDROID..............................................................................M ETHYLTESTOSTERONE ANTABUSE DISULFIRAM

AQUAMEPHYTON............................................................................. PHYTONADIONE

AURALGAN......................................................................... BENZOCAINE, ANTIPYRINE

AZO-GANTANOL.................................................... SULFAM ETHOXAZOLE, PHENAZOPYRIDINE

AZO-GANTRISIN ....................................................... SULFISOXAZOLE PHENAZOPYRIDINE HCl

AZULFADINE ................................................................................. SULFASALAZINE

BENADRYL ............................................................................DIPHENHYDRAM INE HCl

CYANOCOBALAM IN

BICILLIN............................................................................ PENICILLIN G BENZATHINE

BRETHINE ............................................................................. TERBUTALINE SULFATE

CHLOR-TRIMETON ............................................................. CHLORPHENIRAMINE MALEATE

COL-BENEMID .................................................................... PROBENECID W/ COLCHICINE

CYCLANDELATE

DECADRON ................................................................................. DEXAM ETHASONE

DESQUAM .................................................................................BENZOYL PEROXIDE

DIMETANE DX ................................ BROM PHENIRAM INE, DEXTROM ETHORPHAN, PSEUDOEPHEDRINE

DIUPRESS......................................................................CHLOROTHIAZIDE W/ RESERPINE

DONNATAL................................................................... ATROPINE SULFATE COM POUND

DRAMAMINE ...............................................................................DIMENHYDRINATE

DRIXORAL.................................................................................. (p roduct reformulated)

ECONOPRED ......................................................................... PREDNISOLONE ACETATE

ELIXOPHYLLINE KI ......................................................... THEOPHYLLINE, POTASSIUM IODIDE

EMPIRIN W/ CODEINE ......................................................... ASPIRIN W/ CODEINE PHOSPHATE

ESTINYL .................................................................................. ETHINYL ESTRADIOL

EXNA ......................................................................................... BENZTHIAZIDE

FEDAHIST ............................................. PSEUDOEPHEDRINE HCl, CHLORPHENIRAMINE MALEATE

GLAUCON ....................................................................................EPINEPHRINE HCl

GRANULEX ............................................................... TRYPSIN, BALSAM PERU, CASTOR OIL

HALOTESTIN .............................................................................FLUOX\YM ESTERONE

HYCOMINE ..........................................HYDROCODONE BITARTRATE W/ PHENYLPROPANOLAM INE

HYDROPRES ........................................................... HYDROCHLOROTHIAZIDE W/ RESERPINE

ISOPTO CARPINE ............................................................................. PILOCARPINE HCl

ISORDIL TEMBID ....................................................................... ISOSORBIDE DINITRATE

ISUPREL .................................................................................. ISOPROTERENOL HCl

KAON ................................................................................POTASSIUM GLUCONATE

KENALOG ....................................................................... TRIAMCINOLONE DIACETATE

LARODOPA .........................................................................................LEVODOPA

LEVSIN ............................................................................. L-HYOSCYAMINE SULFATE

LIBRAX........................................................... CHLORDIAZEPOXIDE W/CLIDINIUM BROM IDE

MANDELAMINE ..................................................................METHENAMINE MANDELATE

MEBARAL ................................................................................... M EPHOBARBITAL

MENEST ...............................................................................EST ROGENS, EST ERIFIED

METALONE T.B.A ................................................................... PREDNISOLONE TEBUTATE

MICRONASE ....................................................................................... GLYBURIDE

M AGNESIUM SALICYLATE NEO-SYNEPHRINE ......................................................................... PHENYLEPHRINE HCl 8/16/02 105 CMR - 4124

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

720.200 continued

720.200: continued BRAND SEE CHLORAL HYDRATE PAMELOR .................................................................................NORTRIPTYLINE HCl

PHENERGAN PLAIN ....................................................................... PROM ETHAZINE HCl

PONTOCAINE .................................................................................TETRACAINE HCl

PROSED ................................. M ETHENAM INE COM BINATION (M ETHENAM INE, PHENYLSALICYLATE,

AT ROPINE SULFAT E, HYOSCYAM INE, BENZ OIC ACID M ET HYLENE BLUE) PROSTIGMINE .................................................................NEOSTIGMINE METHYLSULFATE

PYRIDIUM ..............................................................................PHENAZOPYRIDINE HCl

QUINAMM ..................................................................................QUININE SULFATE

SALUTENSIN ............................................................... HYDROFLUM ETHIAZIDE, RESERPINE

SANOREX.......................................................................................... M AZINDOL

SERAPES.............................................. HYDRALAZINE HCl, HYDROCHLOROTHIAZIDE, RESERPINE

SLO-PHYLLIN GG .................................................................THEOPHYLLINE, GUAIFENESIN

SLO-PHYLLIN ....................................................... T HEOPHYLLINE (NON-SUST AINED RELEASE)

SSKI ....................................................................................... POTASSIUM IODIDE

SUDAFED ...............................................................................PSEUDOEPHEDRINE HCl

SYNTHROID .........................................................................LEVOTHYROXINE SODIUM

TENUATE................................................................................ DIETHYLPROPION HCl

TESTOSTERONE TUINAL ......................................................AM OBARBITAL SODIUM , SECOBARBITAL SODIUM

VASODILAN ..................................................................................... ISOXSUPRINE

8/16/02 105 CMR - 4125

105 CMR: DEPARTMEN T O F PUBLIC HEALTH

(PAGES 4127 THROUGH 4132 ARE RESERVED FOR FUTURE USE.)

8/16/02 105 CMR - 4126